PCSK9
内分泌学
内科学
碳水化合物代谢
低密度脂蛋白受体
医学
糖尿病
分解代谢
胆固醇
可欣
脂质代谢
前蛋白转化酶
新陈代谢
脂蛋白
作者
Theodosios D. Filippatos,Sebastien Filippas‐Ntekouan,Eleni Pappa,Thalia Panagiotopoulou,Vasilis Tsimihodimos,Moses Elisaf
出处
期刊:World Journal of Diabetes
[Baishideng Publishing Group Co (World Journal of Diabetes)]
日期:2017-01-01
卷期号:8 (7): 311-311
被引量:19
标识
DOI:10.4239/wjd.v8.i7.311
摘要
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a paramount role in the degradation of low-density lipoprotein (LDL) receptors (LDLR) on the hepatic cells surface and subsequently affects LDL particles catabolism and LDL cholesterol (LDL-c) levels. The anti-PCSK9 monoclonal antibodies lead to substantial decrease of LDL-c concentration. PCSK9 (which is also expressed in pancreatic delta-cells) can decrease LDLR and subsequently decrease cholesterol accumulation in pancreatic beta-cells, which impairs glucose metabolism and reduces insulin secretion. Thus, a possible adverse effect of PCSK9 inhibitors on carbohydrate metabolism may be expected by this mechanism, which has been supported by the mendelian studies results. On the other hand, clinical data have suggested a detrimental association of PCSK9 with glucose metabolism. So, the inhibition of PCSK9 may be seen as a double-edged sword regarding carbohydrate metabolism. Completed clinical trials have not shown a detrimental effect of PCSK9 inhibitors on diabetes risk, but their short-term duration does not allow definite conclusions.
科研通智能强力驱动
Strongly Powered by AbleSci AI